Acute Myeloid Leukemia Stem Cells in Minimal/Measurable Residual Disease Detection

• Published in: Cancers Vol. 15; no. 10; p. 2866
• Main Authors: Srinivasan Rajsri, Kritika, Roy, Nainita, Chakraborty, Sohini
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 22.05.2023; MDPI
• Subjects: Acute myeloid leukemia; Cancer; Chemotherapy; Cloning; Cytogenetics; Cytotoxicity; Hemopoiesis; Leukemia; Malignancy; Medical research; Minimal residual disease; Morphology; Mutation; Oncology, Experimental; Pathogenesis; Patients; Physiology; Remission; Remission (Medicine); Review; Risk assessment; Stem cells; Strategic planning (Business); blasts; relapse; immunophenotype; acute myeloid leukemia (AML); multiparametric flow cytometry (MFC); leukemia stem cells (LSCs); measurable/minimal residual disease (MRD)
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15102866

Acute myeloid leukemia (AML) is a hematological malignancy characterized by an abundance of incompletely matured or immature clonally derived hematopoietic precursors called leukemic blasts. Rare leukemia stem cells (LSCs) that can self-renew as well as give rise to leukemic progenitors comprising the bulk of leukemic blasts are considered the cellular reservoir of disease initiation and maintenance. LSCs are widely thought to be relatively resistant as well as adaptive to chemotherapy and can cause disease relapse. Therefore, it is imperative to understand the molecular bases of LSC forms and functions during different stages of disease progression, so we can more accurately identify these cells and design therapies to target them. Irrespective of the morphological, cytogenetic, and cellular heterogeneity of AML, the uniform, singularly important and independently significant prognosticator of disease response to therapy and patient outcome is measurable or minimal residual disease (MRD) detection, defined by residual disease detection below the morphology-based 5% blast threshold. The importance of LSC identification and frequency estimation during MRD detection, in order to make MRD more effective in predicting disease relapse and modifying therapeutic regimen is becoming increasingly apparent. This review focuses on summarizing functional and cellular composition-based LSC identification and linking those studies to current techniques of MRD detection to suggest LSC-inclusive MRD detection as well as outline outstanding questions that need to be addressed to improve the future of AML clinical management and treatment outcomes.